Current Clopidogrel News and Events | Page 7

Current Clopidogrel News and Events, Clopidogrel News Articles.
Sort By: Most Relevant | Most Viewed
Page 7 of 7 | 280 Results
Desensitization protocol overcomes allergy to clopidogrel
A careful desensitization protocol can help patients overcome allergic reactions to anti-clotting medication critical to preventing new blockages inside coronary stents, according to a study being presented at the Society for Cardiovascular Angiography and Interventions (SCAI) 29th Annual Scientific Sessions in Chicago, May 10-13. (2006-05-11)

ESC statement on the CHARISMA trial on Clopidogrel (Plavix®)
The ESC would like to remind patients that dual antiplatelet therapy is an essential, approved and recommended therapy for one year in patients post ACS without ST-segment elevation, and for at least six months post stenting. (2006-03-17)

Dangers of stopping clopidogrel (Plavix®) for patients with stents and certain other conditions
Recent media reports regarding the results of the CHARISMA Trial may be misinterpreted by patients with coronary stents and other conditions*, causing these patients to inappropriately stop taking the anti-clotting drug clopidogrel (Plavix®). Patients taking Plavix® for any reason should consult with their cardiologist or other health care provider before stopping this medication. (2006-03-16)

New generation of cardiac interventions, therapies optimize heart disease care
Research presented today at the American College of Cardiology's 55th Annual Scientific Session and the inaugural Innovation in Intervention: i2 Summit 2006 in Atlanta, Ga., highlights critical advances in the treatment of cardiovascular disease. The studies define add-on therapies that improve the treatment of heart attack and increase the long-term success of stenting and bolster the promise of stem-cell therapy in patients with chronic heart disease. (2006-03-14)

Post-stent maintenance therapies questioned
Patients admitted to the hospital with an acute coronary syndrome (ACS) are often treated with a catheter-based procedure known as percutaneous coronary intervention, or PCI. But doctors are unclear about the optimal antithrombotic therapy to prescribe after procedure to prevent clotting, and new research suggests a possible alternative, according to a study presented today at the American College of Cardiology's 55th Annual Scientific Session. (2006-03-14)

Jefferson scientists test new device for fixing holes in hearts of young stroke patients
Interventional cardiologists have been using transcatheter devices designed to close PFO successfully for many years. Now in a multicenter study to be presented at the American College of Cardiology's 55th Scientific Session (Monday, March 13 at 10 a.m.), researchers from Thomas Jefferson University Hospital assess the initial US experience with the Cardia PFO closure device for the prevention of recurrent stroke in patients with PFO. (2006-03-13)

Medication reduces risk of adverse events for patients with acute coronary syndromes undergoing PCI
Patients with acute coronary syndromes who were pre-treated with the anti-platelet agent clopidogrel before undergoing a procedure such as balloon angioplasty or stent placement had a reduced risk of adverse events if they received the anti-clotting drug abciximab, according to a study that will appear in the April 5 issue of JAMA. The study is being released early online to coincide with its presentation at the American College of Cardiology annual conference. (2006-03-13)

Physicians slower to incorporate newer heart drug treatments
An analysis of the treatment received by more than 100,000 heart patients has shown that physicians' prescription practices for drugs proven effective for treating heart disease has shown steady improvement over the past three years, cardiologists at the Duke Clinical Research Institute (DCRI) have concluded. (2005-11-14)

Women are receiving less aggressive treatment for chest pain and heart attacks than men, study finds
Women with one of a group of heart problems known as acute coronary syndromes (ACS) are almost one-third less likely to receive invasive treatments when compared with men with the same conditions, according to data from an international study of more than 12,000 people. Consequently, women are about one-sixth more likely than men to suffer recurrent heart problems, reports the new paper, to be published in the Nov. 15 issue of the Journal of the American College of Cardiology. (2005-11-10)

New drug could substantially reduce deaths from heart attack
Adding the anti-platelet drug clopidogrel to aspirin for the emergency treatment of heart attacks could save thousands of lives each year, according to a study published in this week's issue of The Lancet. The treatment should be considered routinely for suspected heart attacks, state the authors, as it can safely reduce mortality in hospital for a wide range of patients. (2005-11-03)

Results of the ELISA II trial
Aspirin and Clopidogrel are widely used and proven to be effective in the treatment of an acute coronary syndrome (ACS). (2005-09-06)

Part of drug trial for patients with atrial fibrillation discontinued
Study treatments for the ACTIVE W trial of the ACTIVE (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) program have been discontinued due to a significant difference in efficacy, in favour of the standard oral anticoagulation (OAC) over antiplatelet therapy (clopidogrel plus aspirin). (2005-09-06)

Study on acute coronary syndromes shows new anti-thrombotic therapy effective, safer for patients
A Canadian-led study involving researchers from 41 countries has demonstrated in a study of acute coronary syndromes (ACS) that a new anti-thrombotic therapy is safer and as effective as the traditional therapy used in preventing heart attacks, death and ischemia in people with serious heart conditions. (2005-09-05)

New anti-thrombotic therapy effective, safer for patients
The OASIS-5/MICHELANGELO study, presented today at the European Society of Cardiology meeting in Stockholm, Sweden, showed that fondaparinux, a new anti-thrombotic therapy, was as effective as enoxaparin in preventing heart attacks, death and ischemia (reduction in blood supply to the tissues) at nine days after an event but demonstrated a dramatic reduction in major bleeding. The study indicated patients had a lower mortality rate at the one-month mark after an acute coronary event. (2005-09-05)

Medication reduces risk of heart attack and cardiovascular death before and after angioplasty
Use of the antiplatelet drug clopidogrel before a coronary angioplasty reduced the risk of cardiovascular death, heart attack or stroke within 30 days following the procedure, according to an article in the September 14 issue of JAMA. (2005-09-04)

Tip sheet Annals of Internal Medicine, Aug. 16, 2005
The current issue of Annals of Internal Medicine includes: 1. Study: Vulnerable older patients who receive quality care live longer; 2. Warfarin plus aspirin benefits some heart patients. (2005-08-15)

Aspirin treatment failure warning
Treatment failures occur with any drug and aspirin is no exception. Evidence is growing that some people will not respond to the anti-coagulant action of aspirin and the drug will not protect against cardiovascular events despite its regular intake. (2005-08-09)

Blacks less likely to get expensive, newer heart treatments
Blacks who suffer the most common type of cardiac ischemia -- non-ST-elevation acute coronary syndrome -- are less likely than whites to receive expensive or newer evidence-based treatments. (2005-03-15)

Emergency clopidogrel could save thousands of lives-46,000-patient heart attack trial results
Adding the anti-platelet drug clopidogrel to aspirin for the emergency treatment of heart attacks could save thousands of lives a year worldwide and prevent thousands of repeat heart attacks and strokes. But caution needed with emergency treatment by beta-blocker metoprolol as it cuts risk of repeat heart attacks and ventricular fibrillation but raises risk of cardiac shock - findings from 46,000-patient trial presented Wednesday 9 March at ACC conference, Orlando. (2005-03-09)

St. John's wort amplifies effect of blood thinner Plavix
The widely used herbal remedy St. John's wort appears to amplify the action of the popular blood-thinning drug clopidogrel, sold as Plavix, a small new clinical study finds. The effect could increase the risk of bleeding among those who take both substances. (2005-03-06)

Three anti-platelet drugs used in combination are safe
The use of three platelet inhibitory drugs -- cilostazol, clopidogrel and aspirin -- has resulted in a significant reduction of thrombotic complications in the primary and secondary prevention of heart attacks. But is it safe to use these medications together -- or in combination do they increase the risk of bleeding? And will patients comply with taking three pills? Emory researchers say the answer to both questions is (2005-03-06)

Low-dose aspirin and stomach ulcer medications better for heart patients with GI complications
Heart patients with gastrointestinal complications should use low doses of aspirin combined with drugs that treat stomach ulcers rather than taking the anti-platelet drug Plavix, which has been thought to reduce bleeding ulcers, according to a gastroenterologist at UT Southwestern Medical Center and the Dallas Veterans Affairs Medical Center. (2005-01-19)

ESC Congress 2004: ICTUS study shows no benefit from early PCI/CABG in high risk unstable angina
Dutch clinical investigators will present data during the Hotline II session on Sunday afternoon, August 29th, ESC Congress 2004, Munich, Germany, showing that modern medical treatment, and angiography followed by PCI or CABG in selected patients (selective invasive strategy), may be equally effective. (2004-08-29)

Combination anti-clotting therapy raises bleeding risk for people at high risk of recurrent stroke
The combination of two anti-clotting agents, aspirin and clopidogrel-- known to be beneficial for people with cardiovascular disease--should not be recommended treatment for patients who have cerebrovascular disease, conclude authors of a study in this week's issue of The Lancet. (2004-07-22)

Some heart attack patients may be resistant to blood thinner
A substantial proportion of heart attack patients may be resistant to the blood thinner clopidogrel - and face an increased risk of recurrent blockages, researchers report in today's rapid access issue of Circulation: Journal of the American Heart Association. (2004-06-08)

Some heart attack patients may be resistant to blood thinner
A substantial proportion of heart attack patients may be resistant to the blood thinner clopidogrel - and face an increased risk of recurrent blockages. (2004-06-07)

Multi-center trial compares three medications in patients with heart failure
Results of an international study led by researchers at the San Francisco VA Medical Center (SFVAMC) suggest that there is no major difference between three medications often prescribed for patients with chronic heart failure to prevent death, heart attack and stroke. However, the results leave important questions unresolved, according to the lead investigator. (2004-03-09)

Aspirin is most cost effective way to prevent heart disease
Aspirin and blood pressure lowering drugs can prevent heart disease at a fraction of the cost of cholesterol lowering drugs (statins) and clopidogrel (an anti-clotting drug), finds a study in this week's BMJ. (2003-11-27)

Welcome alternative to warfarin for people at high risk of stroke
Results of an international study in this week's issue of THE LANCET provide strong evidence that the oral direct thrombin-inhibitor ximelagatran could be a safe and effective alternative to warfarin in reducing stroke among people with atrial fibrillation. (2003-11-20)

Antiplatelet drug found to reduce risk of recurrent heart attacks and stroke is cost-effective
The antiplatelet medicine clopidogrel is not only effective in reducing the risk of recurrent heart attack and stroke, it is also extremely cost-effective, according to data presented today by researchers from Emory University at the American Heart Association's Scientific Sessions. (2003-11-12)

Nursing home residents, minorities under-treated for recurrent stroke
Only half of elderly Americans in nursing homes are treated to prevent recurrent strokes, according to a review of nursing home admission records reported in today's rapid access issue of Stroke: Journal of the American Heart Association. (2003-10-09)

Clopidogrel reduces death, stroke, heart attack now and later
The blood thinner clopidogrel, when used with aspirin, reduced the risk of subsequent heart attack, stroke and death in people who came to the emergency department with new or increasing chest pain or a heart attack, according to a report in today's rapid access issue of Circulation: Journal of the American Heart Association. (2003-02-17)

Aspirin within two days of ischemic stroke reduces deaths
Giving patients aspirin within 48 hours of the onset of an acute ischemic stroke can reduce death and severity of stroke, according to a joint scientific statement from the American Stroke Association and the American Academy of Neurology. (2002-07-08)

Aspirin within two days of ischemic stroke reduces deaths
Giving patients aspirin within 48 hours of the onset of an acute ischemic stroke can reduce death and severity of stroke, according to a joint scientific statement from the American Stroke Association and the American Academy of Neurology. (2002-07-08)

VA trial to weigh aspirin against other anti-clotting drugs in heart disease patients
A large international trial begun recently by researchers at the San Francisco Veterans Affairs Medical Center that will match two old drugs, aspirin and warfarin, against each other and against the newer drug clopidogrel to see which one prevents more heart attacks, strokes, and deaths in patients with chronic heart failure. (2000-12-10)

Clot-preventing drug can cause potentially fatal blood disorder
Northwestern University researchers Charles L. Bennett, M.D., and Charles J. Davidson, M.D., report that clopidogrel, a new blood clot-preventing drug taken by one million patients, can cause a rare but potentially fatal blood disease known as thrombotic thrombocytopenic purpura. The disorder almost always appears within two weeks of starting clopidogrel therapy. (2000-04-19)

American Heart Association updates 'mini stroke' guidelines
New blood thinning medications are among the significant medical and surgical advances that have occurred over the past five years for the treatment of (1999-11-03)

Antiplatelet drugs: comparison of clopidogrel with aspirin
Antiplatelet agents may improve the outlook for heart attack and stroke patients, according to researchers in Stroke: Journal of the American Heart Association. (1999-08-05)

Emory Receives $14 Million Federal Grant To Coordinate 50-Site Brain Attack Prevention Trial
The National Institute of Neurological Disorders and Stroke of the National Institutes of Health has funded the Warfarin- Aspirin Symptomatic Intracranial Disease (WASID) study, and Emory University has been awarded more than $14 million from the institute to coordinate a five-year trial during which 806 patients will be evaluated at 50 sites in North America. (1999-03-31)

Aspirin's Preventive Action In Heart Attacks Tied To Genetics
Researchers who were looking for the reason why simple aspirin use protects some people from developing heart attacks have traced the mechanism back to a specific genetic factor present on the surface of clotting cells called platelets. (1998-04-25)

Page 7 of 7 | 280 Results
   First   Previous   Next      Last   
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.